Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.81% and currently trading at $912.00. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Eli Lilly & Co. stock rises Thursday, still underperforms market
Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and the Dow Jones Industrial Average DJIA rising 1.
Prediction: This Will be Eli Lilly's Next Big Move.
This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped revenue to soar in the double digits -- and that's resulted in a surging share price too,
3d
Lilly Wants Records of People Who Took Weight-Loss Knockoffs
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...
USA Today
6d
New eczema drug from Eli Lilly receives FDA approval for children and adults
On Friday, the U.S. Food and
Drug
Administration approved Eli
Lilly
's eczema
drug
for use in adults and children 12 and ...
95.3 MNC
19h
FDA approves Eli Lilly’s new eczema treatment, Ebglyss
The U.S. Food and Drug Administration has approved Indianapolis-based Eli Lilly's new treatment for moderate to severe eczema ...
2d
Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
5d
on MSN
US FDA approves Eli Lilly's drug for eczema
Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above ...
4d
on MSN
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...
1d
Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
1d
FTC sues drug middlemen over manipulating the insulin market
The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...
Ibj.com
4d
Eli Lilly requests records of people who took copies of its weight-loss drug
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
2d
The Price War in Weight-Loss Drugs Is Here
Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...
1d
Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading Range
Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback